PIKEVILLE MEDICAL CENTER
- Type
- Teaching hospital
- Where
- PIKEVILLE, KY
- Medicare CCN
- 180044
- Received
- $118,142 in 49 records, 2020 ($5,142 general, $112,999 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Pikeville Medical Center, Inc. Fuzzy (name and state)
- Nonprofit contractor: PIKEVILLE MEDICAL CENTER Fuzzy (name and state)
- Plan sponsor: PIKEVILLE MEDICAL CENTER, INC. Fuzzy (name and state)
- Federal award recipient: PIKEVILLE MEDICAL CENTER INC Fuzzy (name and state)
- Lobbying client: PIKEVILLE MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: PIKEVILLE MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: PIKEVILLE MEDICAL CENTER, INC. Fuzzy (name and state)
- Nonprofit: PIKEVILLE MEDICAL CENTER INC Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 7 | $5,142 |
| 2020 | Research payment | 42 | $112,999 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Merck Sharp & Dohme LLC | 37 | $68,444 | 2020 |
| GlaxoSmithKline, LLC. | 3 | $32,036 | 2020 |
| Radius Health, Inc. | 2 | $12,519 | 2020 |
| Bard Peripheral Vascular, Inc. | 2 | $3,800 | 2020 |
| Olympus America Inc. | 1 | $775 | 2020 |
| GE HEALTHCARE | 2 | $331 | 2020 |
| Concordance Healthcare Solutions, LLC | 1 | $177 | 2020 |
| Nonin Medical, Inc. | 1 | $57 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 42 | $112,999 |
| Gift | 5 | $4,189 |
| Education | 1 | $775 |
| Food and Beverage | 1 | $177 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-22 | GlaxoSmithKline, LLC. | $14,431 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN | 2020 | |
| 2020-12-22 | GlaxoSmithKline, LLC. | $9,805 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN | 2020 | |
| 2020-11-12 | Merck Sharp & Dohme LLC | $39,083 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab | 2020 |
| 2020-11-12 | Merck Sharp & Dohme LLC | $548 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab | 2020 |
| 2020-11-12 | Merck Sharp & Dohme LLC | $509 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab | 2020 |
| 2020-10-13 | Merck Sharp & Dohme LLC | $26,055 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-10-09 | Concordance Healthcare Solutions, LLC | $177 | Food and Beverage (8 payments) | In-kind items and services | 2020 | ||
| 2020-10-08 | Radius Health, Inc. | $8,756 | Research payment | Cash or cash equivalent | A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATAS | 2020 | |
| 2020-07-29 | Nonin Medical, Inc. | $57 | Gift | In-kind items and services | Device, Oximetry | 2020 | |
| 2020-07-28 | Merck Sharp & Dohme LLC | $759 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab | 2020 |
| 2020-07-02 | Merck Sharp & Dohme LLC | $240 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab | 2020 |
| 2020-06-08 | Merck Sharp & Dohme LLC | $20 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-05-28 | Radius Health, Inc. | $3,762 | Research payment | Cash or cash equivalent | A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATAS | 2020 | |
| 2020-05-12 | GlaxoSmithKline, LLC. | $7,800 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN | 2020 | |
| 2020-05-11 | Olympus America Inc. | $775 | Education | In-kind items and services | ENT General Device, Ear/Nose/Throat | 2020 | |
| 2020-04-08 | Merck Sharp & Dohme LLC | $356 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $117 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $110 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $36 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $36 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $35 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $31 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $30 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $24 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $22 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $22 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $21 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $20 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $17 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $17 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $15 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $12 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $12 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $9 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $9 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $8 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $6 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-04-08 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-02-14 | Merck Sharp & Dohme LLC | $240 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pe | 2020 |
| 2020-01-29 | Bard Peripheral Vascular, Inc. | $3,464 | Gift | In-kind items and services | VIDA Device, BD Interventional - Peripheral Intervention | 2020 | |
| 2020-01-29 | Bard Peripheral Vascular, Inc. | $336 | Gift | In-kind items and services | CROSSER Device, BD Interventional - Peripheral Intervention | 2020 | |
| 2020-01-01 | GE HEALTHCARE | $191 | Gift | In-kind items and services | 2020 | ||
| 2020-01-01 | GE HEALTHCARE | $140 | Gift | In-kind items and services | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Pikeville, KY, county Pike County, KY, state Kentucky; placed by its city name.
| Measure | Place (city or town) Pikeville, KY | County Pike County, KY | State Kentucky |
|---|---|---|---|
| Population B01003 | 7,490 | 56,727 | 4,534,824 |
| Population, 2020 census P1 | 7,754 | 58,669 | 4,505,836 |
| Median age B01002 | 40.4 | 43.3 | 39.1 |
| Under 18 B01001 | 15.1% | 20.3% | 22.6% |
| 65 and over B01001 | 17.1% | 20.1% | 17.3% |
| Households B11001 | 3,323 | 24,284 | 1,814,469 |
| Foreign born B05002 | 4.6% | 0.9% | 4.7% |
| Median household income B19013 | $39,955 | $44,312 | $63,726 |
| Median family income B19113 | $73,732 | $63,028 | $81,505 |
| Per capita income B19301 | $33,301 | $27,048 | $35,821 |
| Poverty rate B17001 | 27.1% | 24.4% | 16.1% |
| Unemployment rate B23025 | 3.2% | 5.2% | 4.9% |
| Civilian labor force B23025 | 2,766 | 20,300 | 2,152,038 |
| Mean commute (minutes) B08013 | 13.4 | 25.3 | 24.0 |
| Bachelor's degree or higher B15003 | 40.4% | 17.8% | 27.6% |
| Housing units B25001 | 3,623 | 29,044 | 2,023,116 |
| Owner-occupied B25003 | 40.8% | 75.3% | 68.3% |
| Renters B25003 | 59.2% | 24.7% | 31.7% |
| Median home value B25077 | $263,800 | $112,000 | $205,600 |
| Median gross rent B25064 | $862 | $858 | $967 |
| White, not Hispanic B03002 | 89.6% | 93.9% | 81.5% |
| Black B03002 | 3.5% | 0.6% | 7.6% |
| Hispanic or Latino B03002 | 1.9% | 1.3% | 5.0% |
| Asian B03002 | 2.4% | 0.6% | 1.6% |
| American Indian and Alaska Native B03002 | 0.0% | 0.0% | 0.1% |
Economy now FRED unemployment 4.7% in Sep 2026 (4.5% a year earlier); per capita personal income $60,835 in 2025, up 29% in five years (+3.9% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Pikeville, KY.
Comments